reviews and ratings and there are plenty of competitions that recognize top strains. Imagine if a leading cannabis data company such as Knalysis Technologies Inc (part of the Canada House Wellness Group) reveals which strains appear to best treat different conditions and what if those different strains were to reveal a similar terpene profile? A lot of what-ifs but this is an exploratory and speculative industry in many
aspects with medical R&D and clinical trials all but in their infancy.
Consumer and patient preference as well as “science” may be powerful forces that determine the winners and the losers and that in turn will impact investors. Terpenes may also prove successful for other reasons and here are just two examples.
1) Myrcene is also attributed to increased bioavailability as well as efficacy. In other words, quicker absorption and amplified effect. Quicker absorption sounds well suited to edibles and beverages and for wanting something stronger than 35 THC maximum amount … perhaps a terpene derived efficacy boost may just do the trick.
2) Beta-caryophyllene is the only known terpene that binds with our endogenous cannabinoid system. It has also said to be effective in the treatment of anxiety and depression; however, you are reminded that none of our content infers or suggests medical advice of any kind. As with your invest-ment decisions, it is on you to conduct your own due diligence. I cannot help but ponder that if Beta- caryophy-llene binds with our endo-cannabinoid system then in time could it not be used as delivery system for treatments such as immunotherapy?
Could cannabis itself be an effective parallel treatment with modern medicine andscience? Many say yes and more and more advocate that cannabis could replace conventional pharmaceuticals
179